At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 206 enrolled
Drug / intervention
GSK573719 +2 moredrug
Likely dose
GSK573719 62.5 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 3 clinical trial evaluating GSK573719 and Placebo for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 206 participants across 27 sites in 3 countries.
Detailed Summary
The purpose of this study is to assess if 12 weeks' treatment with GSK573719 Inhalation Powder is safe and effective compared with placebo or no active drug intake, when administered once-daily in subjects with Chronic Obstructive Pulmonary Disease (COPD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesGermany, Japan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJul 2011
Primary CompletionFeb 2012
Study CompletionFeb 2012
TodayJul 2026
First PostedJul 4, 2011
Enrollment StartJul 1, 2011
Primary CompletionFeb 1, 2012
Study CompletionFeb 13, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.0 years ago
Interventions
GSK573719drug
62.5 mcg
GSK573719drug
125mcg
Placeboother
Placebo